This article is more than 5 years old. Information may no longer be current.

Giant Cell Arteritis: Overcoming the Limitations of Conventional Agents With Biologic Therapy

Issue: April 2018

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Giant cell arteritis (GCA) is the most common form of medium- and large-vessel vasculitis. If left untreated, patients with GCA are at increased risk for a range of short- and long-term complications. Diagnosis of GCA remains difficult due to the nonspecific nature of many early symptoms. Until recently, therapeutic options were limited to prolonged, high-dose glucocorticoid therapy, which has the potential for many undesirable side effects. In this CME activity, expert faculty will discuss the clinical and immunopathologic features of GCA, current therapeutic options, as well as data for new and emerging agents. Case-based discussion will provide practical strategies for overcoming the diagnostic and treatment challenges of GCA.

Click here to view this activity.

Learning Objectives:

Upon completion of this educational activity, the participant will be better able to:

• Review the pathophysiology and clinical symptomology of GCA.
• Examine the short- and long-term complications associated with GCA as well as the importance of early diagnosis and treatment.
• Identify patients with GCA in a timely and accurate manner based on appropriate clinical work-up and diagnostic modalities.
• Examine the advantages and disadvantages of conventional treatments for the management of GCA and related vasculitides.
• Apply knowledge of the latest clinical evidence to the optimal treatment of patients with GCA.

Overview

Author(s)/Faculty: Leonard H. Calabrese, DO; Eamonn Molloy, MD, MS, FRCPI; John H. Stone, MD, MPH
Source: Healio Rheumatology Education Lab
Type: Lecture
Articles/Items: 6
Release Date: 1/31/2018
Expiration Date: 1/30/2019
Credit Type: CME
Number of Credits: 1.5
Cost: Free
Provider: Vindico Medical Education

CME Information

Sponsorship Statement: This continuing medical education activity is provided by Vindico Medical Education.

Support Statement: This activity is supported by an educational grant from Genentech, Inc

Target Audience: The intended audience for this activity is rheumatologists and other health care professionals involved in the treatment of patients with giant cell arteritis (GCA).